Drug intelligence / Profile preview

SPH9788

Development stage: Phase 1
Lead developer: Shanghai Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SPH9788 is an investigational small molecule drug developed by Shanghai Pharmaceuticals Holding for an undisclosed indication. It is currently in phase 1 clinical trials in China, where its safety, tolerability, and pharmacokinetic properties are being evaluated in healthy volunteers. The drug is administered orally in tablet form. As of now, the specific mechanism of action and therapeutic target have not been publicly disclosed[1][2][3].

Beyond the preview

Go deeper on SPH9788.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH9788.

Explore the full profile